Last reviewed · How we verify
Ilomedin and standard low dose treatment
Ilomedin and standard low dose treatment is a Small molecule drug developed by Thrombologic ApS. It is currently in Phase 1 development.
At a glance
| Generic name | Ilomedin and standard low dose treatment |
|---|---|
| Sponsor | Thrombologic ApS |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Endothelial Dysfunction in Resuscitated Cardiac Arrest (PHASE2)
- Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis (PHASE2)
- Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ilomedin and standard low dose treatment CI brief — competitive landscape report
- Ilomedin and standard low dose treatment updates RSS · CI watch RSS
- Thrombologic ApS portfolio CI
Frequently asked questions about Ilomedin and standard low dose treatment
What is Ilomedin and standard low dose treatment?
Ilomedin and standard low dose treatment is a Small molecule drug developed by Thrombologic ApS.
Who makes Ilomedin and standard low dose treatment?
Ilomedin and standard low dose treatment is developed by Thrombologic ApS (see full Thrombologic ApS pipeline at /company/thrombologic-aps).
What development phase is Ilomedin and standard low dose treatment in?
Ilomedin and standard low dose treatment is in Phase 1.